Mai A L, Yim C, O'Rourke K, Heathcote E J
Department of Medicine, Toronto Hospital, University of Toronto, Ontario, Canada.
J Clin Gastroenterol. 1996 Jun;22(4):299-304. doi: 10.1097/00004836-199606000-00012.
A retrospective analysis of 99 hepatitis B-positive homosexual men with known human immunodeficiency virus (HIV) status was conducted to study the interaction of concurrent HIV infection on the course of their chronic hepatitis B virus (HBV) infection. All 99 subjects had chronic hepatitis B, 43 of whom were HIV antibody negative and 56 of whom were HIV antibody positive at the time of their initial presentation. Serial serum aminotransferase levels were used as an indirect estimate of the severity of hepatic inflammation. Factors that may influence the course of hepatitis B, HIV status, hepatitis B e antigen (HBeAg)/hepatitis B e antibody (HBeAb) status, alcohol intake, and zidovudine (AZT) therapy were correlated with aminotransferase values. Overall, there was no difference in mean serum alanine aminotransferase (ALT) levels between HIV antibody-negative and HIV antibody-positive patients. There is a higher prevalence rate of HBeAg in HIV antibody-positive patients (p < 0.05), and the seroconversion rate from HBeAg to HBeAb was lower in HIV antibody-positive patients compared with HIV antibody-negative patients (p < 0.05). However, reactivation rates from HBeAb to HBeAg were no different in the HIV antibody-positive and negative hepatitis B carriers. With mild, moderate, or heavy alcohol intake, we observed no statistically significant difference in mean serum alanine aminotransferase levels and no mean serum aspartate aminotransferase levels between HIV antibody-negative patients versus HIV antibody-positive patients. Similarly, there was no significant difference in the pattern of serum aminotransferase in those subjects treated with or without AZT. The mortality rates were higher in HIV antibody-positive patients (n = 8) compared with in HIV antibody-negative patients (n = 2). Seventy-five percent (n = 6) of the HIV antibody-positive patients died from acquired immunodeficiency syndrome (AIDS), and overall only two patients died of liver disease, one in each group. We conclude that there is no overt influence by HIV or the treatment thereof on the course of chronic HBV infection in a population of homosexual men. In HIV-infected patients, death from AIDS predominated; hence, the main target for therapy should be HIV rather than HBV.
对99名已知人类免疫缺陷病毒(HIV)感染状况的乙型肝炎阳性同性恋男性进行了回顾性分析,以研究同时感染HIV对其慢性乙型肝炎病毒(HBV)感染病程的影响。所有99名受试者均患有慢性乙型肝炎,其中43人在初次就诊时HIV抗体阴性,56人HIV抗体阳性。连续血清转氨酶水平被用作肝炎症严重程度的间接估计指标。可能影响乙型肝炎病程的因素,如HIV感染状况、乙肝e抗原(HBeAg)/乙肝e抗体(HBeAb)状态、酒精摄入量以及齐多夫定(AZT)治疗,均与转氨酶值相关。总体而言,HIV抗体阴性和HIV抗体阳性患者的平均血清丙氨酸转氨酶(ALT)水平无差异。HIV抗体阳性患者中HBeAg的患病率较高(p<0.05),与HIV抗体阴性患者相比,HIV抗体阳性患者从HBeAg到HBeAb的血清学转换率较低(p<0.05)。然而,HIV抗体阳性和阴性乙肝携带者从HBeAb到HBeAg的再激活率并无差异。无论酒精摄入量为轻度、中度或重度,我们观察到HIV抗体阴性患者与HIV抗体阳性患者之间的平均血清丙氨酸转氨酶水平以及平均血清天冬氨酸转氨酶水平均无统计学显著差异。同样,接受或未接受AZT治疗的受试者血清转氨酶模式也无显著差异。HIV抗体阳性患者(n = 8)的死亡率高于HIV抗体阴性患者(n = 2)。75%(n = 6)的HIV抗体阳性患者死于获得性免疫缺陷综合征(AIDS),总体上只有两名患者死于肝病,每组各一名。我们得出结论,在同性恋男性群体中,HIV或其治疗对慢性HBV感染病程没有明显影响。在HIV感染患者中,死于AIDS占主导;因此,治疗的主要靶点应是HIV而非HBV。